Detection of mutant p53 protein in workers occupationally exposed to benzidine

Area of Science:

• Occupational Health
• Biomarker Discovery
• Cancer Research

Background:

• Benzidine is a known human carcinogen associated with bladder cancer.
• Early detection of bladder cancer is crucial for improving patient outcomes.
• Mutant p53 protein expression can serve as a potential biomarker for cancer development.

Purpose of the Study:

• To investigate the expression of mutant p53 protein in workers occupationally exposed to benzidine.
• To correlate mutant p53 protein levels with benzidine exposure intensity and Papanicoloau's grading (PG) of exfoliated urothelial cells.
• To assess the utility of mutant p53 protein detection for early bladder cancer diagnosis.

Main Methods:

• Immuno-PCR assay used to detect mutant p53 protein in serum samples from 331 benzidine-exposed workers.
• Exfoliated urothelial cells in urine samples classified using Papanicoloau's grading (PG I, II, III).
• Workers categorized into high, medium, and low exposure groups based on an exposure intensity index.

Main Results:

• Mutant p53 protein levels were significantly higher in medium and high benzidine exposure groups compared to the low exposure group (p<0.05).
• Higher mutant p53 protein levels were observed in PG II and III compared to PG I (p<0.05).
• In medium and high exposure groups, PG II and/or III showed significantly higher mutant p53 protein incidence/quantity than PG I (p<0.05).

Conclusions:

• Mutant p53 protein expression is elevated in workers with higher occupational benzidine exposure.
• Combined detection of mutant p53 protein, exposure level, and urine cytology grading enhances bladder cancer surveillance.
• This approach may improve early detection and diagnosis of bladder cancer in occupationally exposed individuals.